Tesamorelin Peptide Capsules

The regulatory effects of Tesamorelin Peptide Capsules in the neurological field stem primarily from their precise activation of the growth hormone (GH)-insulin-like growth factor 1 (IGF-1) axis, while also maintaining neurotransmitter balance and optimizing the brain microenvironment, thus forming a multi-dimensional neuroprotective network. As a synthetic GHRH analog, the capsules gently stimulate the pituitary gland to secrete GH through sustained-release technology, which in turn induces the liver to synthesize IGF-1. These two factors act synergistically on the central nervous system to exert key physiological effects.

Both GH and IGF-1 can cross the blood-brain barrier and act directly on brain regions closely associated with cognitive functions, such as the hippocampus and cerebral cortex. Among them, IGF-1 promotes the proliferation and differentiation of neural stem cells, accelerates synaptogenesis and remodeling, and enhances synaptic transmission efficiency-synaptic plasticity being the core physiological basis of learning and memory functions. Meanwhile, activation of this axis inhibits neuronal apoptosis pathways, reduces neuronal damage caused by oxidative stress and inflammatory responses, and maintains the homeostasis of the intracerebral microenvironment. In addition, clinical studies have confirmed that it can increase the level of gamma-aminobutyric acid (GABA) in the brain. As a key inhibitory neurotransmitter, GABA regulates neuronal excitability, improves the efficiency of signal transmission between brain cells, and further strengthens the regulatory effect on cognitive functions.

Notably, the sustained-release property of the capsule dosage form is particularly advantageous in this scenario. In contrast to the sharp fluctuations in hormone levels caused by injections, sustained-release capsules enable the steady and continuous elevation of GH and IGF-1 levels, avoiding stress damage to nerve cells induced by hormonal fluctuations. This makes them more suitable for the long-term intervention needs of cognitive aging and neurodegenerative diseases.

Cognitive aging is an inevitable physiological phenomenon in the natural aging process, mainly characterized by memory decline, impaired executive function, and poor concentration. Its core contributing factors include the functional decline of the GH-IGF-1 axis, synaptic dysfunction, and insufficient cerebral perfusion. By targeting and activating relevant pathways, it provide a novel intervention direction for delaying cognitive aging, and the oral dosage form greatly improves medication convenience.

The product can enhance cerebral perfusion capacity and neurotransmitter balance by optimizing the function of the GH-IGF-1 axis, maintain the volume and functional integrity of the hippocampus, and thus slow down the rate of normal cognitive decline. For mild cognitive impairment (MCI), it can specifically improve core cognitive indicators and reduce the risk of progression to dementia. Administering the capsules orally before bedtime can further enhance GH secretion efficiency by leveraging physiological rhythms, exerting a more effective cognitive protective effect. This administration method is also more amenable to popularization due to the convenience of the capsule dosage form.

(2) HIV-associated Neurocognitive Disorders

HIV-infected patients often experience neurocognitive impairment, which is closely related to neuroinflammation induced by viral infection, abnormal fat metabolism, and dysfunction of the GH-IGF-1 axis. Since the product have already been approved for the treatment of HIV-associated lipodystrophy, they can simultaneously intervene in neurocognitive problems while improving metabolic disorders. An ongoing Phase II clinical trial shows that elderly HIV-infected patients receiving it treatment exhibit significant improvements in neurocognitive function, an effect possibly associated with optimized fat metabolism, reduced neuroinflammation, and activation of the GH-IGF-1 axis. For such patients with multisystem impairments, the capsules can achieve a synergistic effect of metabolic conditioning and neuroprotection, simplifying the treatment regimen.

(3) Potential Exploration in Other Neurodegenerative Diseases

In diseases such as spinocerebellar degeneration, the neuroprotective mechanism of it provides new insights for the intervention of such conditions. By promoting neurotransmitter release, inhibiting neurotoxicity, and enhancing the metabolic function of nerve cells, it may exert an adjuvant improving effect on symptoms such as ataxia and motor coordination disorders. In addition, preclinical studies on Alzheimer's disease have found that activation of the GH-IGF-1 axis can reduce the deposition of β-amyloid protein in the brain and inhibit the excessive phosphorylation of tau protein-two core pathological features of Alzheimer's disease. This suggests that it may delay disease progression by targeting these pathological processes, and relevant clinical studies are currently underway.

The raw tesamorelin peptide is a white to off-white crystalline powder, odorless and tasteless, with uniform particle size and good fluidity, providing a high-quality raw material basis for the capsule filling process. In terms of physicochemical solubility, this component is sparingly soluble in water (1–10 mg per 1 mL of water) and almost insoluble in organic solvents such as methanol, ethanol, and acetone. Its solubility is slightly better in neutral to weakly alkaline buffer solutions with a pH of 7.0–8.5. This characteristic is compatible with the acid-base environment in the posterior segment of the human gastrointestinal tract, laying a chemical foundation for the absorption of the Tesamorelin Peptide Capsules.

To meet the clinical requirements of the oral capsule dosage form, targeted optimizations have been made to both the chemical structure of tesamorelin peptide and the selection of excipients. At the structural level, C-terminal amidation modification reduces the lipophilicity of the molecule, balances the lipid-water partition coefficient, enabling the component to dissolve moderately in the gastrointestinal tract and penetrate the intestinal mucosal barrier smoothly for absorption. In terms of excipient selection, anhydrous lactose and microcrystalline cellulose are used as capsule fillers, and magnesium stearate as a lubricant.